Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 1, 2000, Pages 43-50

  Murren, John R ^a   Peccerillo, Kathleen ^a   DiStasio, Susan A ^a   Li, Xin ^a   Leffert, Janine J ^a   Pizzorno, Giuseppe ^a   Burtness, Barbara A ^a   McKeon, Anne ^a   Chi Cheng, Yung ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Combination therapy; Irinotecan; Paclitaxel; Pharmacokinetics

Indexed keywords

IRINOTECAN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG TOLERANCE; FEMALE; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0033935352     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000115     Document Type: Article

References (40)

1. 1. Abigerges D, Chabot GG, Armand J, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210
2. 2. Akerly W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L (1998) Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16: 153
3. 3. Arbuck SG, Takimoto CH (1998) An overview of topoisomerase I-targeting agents. Semin Hematol 35 [3 Suppl 4]: 3
4. 4. Bertrand R, O'Connor PM, Kerrigan D, Pommier Y (1992) Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A: 743
5. 5. Bissery MC, Vrignaud P, Lavelle F (1996) In vivo evaluation of the docetaxel-irinotecan combination. Proc Am Assoc Cancer Res 37: 378
6. 6. Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33: 245
7. 7. Chou T-C, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517
8. 8. Debernardis D, Cimoli G, Parodi S, Russo P (1996) Interactions between taxol and camptothecin. Anticancer Drugs 7: 531
9. 9. Forni M de, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, Madelaine I, Marty ME, Mathieu-Boue A (1994) Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54: 4347
10. 10. Fukuoka M, Masuda N (1994) Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol [Suppl] 34: S105
11. 11. Gianni L (1995) Theoretical and practical aspects of paclitaxel scheduling. Ann Oncol 6: 861
12. 12. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688
13. 13. Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P (1997) Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer HT-29 in vitro and in vivo. Int J Cancer 73: 729
14. 14. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN (1996) Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14: 2713
15. 15. Horowitz SB, Horowitz M (1973) Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 33: 2834
16. 16. Iyer L, Ratain MJ (1998) Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol [Suppl] 42: S31
17. 17. Kano Y, Suzuki K, Akutsu M, Suda K (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50: 604
18. 18. Kaufmann SH (1991) Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129
19. 19. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK (1996) Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88: 734
20. 20. Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Sartorius S, Chen TL, Bowling K, Rowinsky EK (1996) Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 14: 783
21. 21. Klaassen U, Wilke H, Strumberg D, Eberhardt W, Korn M, Seeber S (1996) Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32A: 547
22. 22. Li L, Fraser T, Olin E, Bhuyan B (1972) Action of camptothecin on mammalian cells in culture. Cancer Res 32: 2643
23. 23. Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL (1995) Phase I study of paclitaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B study. J Clin Oncol 13: 2230
24. 24. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351
25. 25. Lopes NM, Adams EG, Pitts TW, Bhuyan BK (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235
26. 26. Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, Schellens JH (1998) Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 41: 307
27. 27. Madden T, Newman RA, Antoun G, Johansen MJ, Ali-Osman F (1998) Low-level taxane exposure increases the activity of topoisomerase I targeted agents. Proc Am Assoc Cancer Res 39: 527
28. 28. Masuda N, Fukuoka S, Kudoh S, Kusunoki Y, Matsui K, Takifuji N, Nakagawa K, Tamanaoi M, Nitta T, Hirashima T, Negoro S, Takada M (1993) Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68: 777
29. 29. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji Y, Kudoh S, Niitani H, Taguchi T (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83: 1164
30. 30. O'Reilly S, Fleming GF, Baker SD, Walczak JR, Bookman MA, McGuire WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK (1997) Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol 15: 177
31. 31. Pei XH, Nakanishi Y, Takayama K, Bai F, Kawasaki M, Tsuruta N, Mizuno K, Hara N (1997) Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs 8: 231
32. 32. Rosen P, Schaaf LJ, Knuth DW, Parson M, Kadib L, Rosen L (1999) Phase I and pharmacokinetic trial of CPT-11 and paclitaxel in patients with advanced cancer. Proc Am Soc Clin Oncol 18: 177
33. 33. Rowinsky EK, Donehower R (1996) Antimicrotubule agents. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy. Lippincott-Raven, Philadelphia, p 263
34. 34. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692
35. 35. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen T-L, Rock MK, Donehower RC (1994) Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54: 427
36. 36. Rushing DA, Tipping SJ, Clouse LH, Mercier RJ, Deedon A, Miller LL (1999) Phase I study of the combination of irinotecan (CPT-11) and paclitaxel (Taxol) in previously treated patients (pts) with small cell carcinoma of the lung (SCCL). Proc Am Soc Clin Oncol 18: 484
37. 37. Saltz L, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP (1996) Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leukovorin in patients with advanced solid tumors. J Clin Oncol 14: 2959
38. 38. Saltz LB, Locker PK, Pirotta N, Elfring GL, Miller LL (1999) Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily x5 LV/FU in patients (pts) with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 18: 233
39. 39. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N (1993) Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol 11: 909
40. 40. Von Hoff DD, Pitot HC, Elfring GL, Mohrland JS, Schaaf LJ, Neff LL, Locker PK, Gibson RE, Miller LL (1997) Irinotecan therapy for patients with previously treated metastatic colorectal cancer: overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 16: 229